Robeco Institutional Asset Management
ALNY icon

Robeco Institutional Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Robeco Institutional Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.6M Buy
188,084
+61,621
+49% +$18.6M 0.07% 247
2026
Q1 		$41.8M Sell
126,463
-18,258
-13% -$6.21M 0.06% 267
2025
Q4 		$57.5M Buy
144,721
+31,647
+28% +$14M 0.08% 226
2025
Q3 		$51.6M Buy
113,074
+16,706
+17% +$6.8M 0.07% 233
2025
Q2 		$31.4M Sell
96,368
-7,113
-7% -$1.97M 0.05% 281
2025
Q1 		$27.9M Buy
103,481
+3,487
+3% +$896K 0.05% 272
2024
Q4 		$23.5M Buy
99,994
+26,426
+36% +$6.95M 0.04% 302
2024
Q3 		$20.2M Buy
73,568
+23,898
+48% +$6.22M 0.04% 331
2024
Q2 		$12.1M Buy
49,670
+20,830
+72% +$3.29M 0.03% 394
2024
Q1 		$4.31M Buy
28,840
+4,705
+19% +$785K 0.01% 580
2023
Q4 		$4.62M Buy
24,135
+16,099
+200% +$2.74M 0.01% 573
2023
Q3 		$1.42M Sell
8,036
-19,107
-70% -$3.65M ﹤0.01% 739
2023
Q2 		$5.16M Sell
27,143
-25,615
-49% -$5.08M 0.01% 548
2023
Q1 		$10.6M Buy
52,758
+771
+1% +$162K 0.03% 429
2022
Q4 		$12.4M Buy
51,987
+12,628
+32% +$2.69M 0.04% 392
2022
Q3 		$7.88M Buy
39,359
+36,948
+1,532% +$7.05M 0.03% 443
2022
Q2 		$352K Sell
2,411
-579
-19% -$82.1K ﹤0.01% 790
2022
Q1 		$488K Buy
2,990
+2,951
+7,567% +$450K ﹤0.01% 776
2021
Q4 		$7K Buy
+39
New +$7.25K ﹤0.01% 899
2021
Q3 		– Sell
-3,602
Closed -$611K – 917
2021
Q2 		$611K Sell
3,602
-5,208
-59% -$763K ﹤0.01% 781
2021
Q1 		$1.24M Sell
8,810
-5,444
-38% -$819K ﹤0.01% 712
2020
Q4 		$1.85M Sell
14,254
-20,599
-59% -$2.75M ﹤0.01% 669
2020
Q3 		$5.07M Sell
34,853
-25,534
-42% -$3.63M 0.02% 513
2020
Q2 		$8.94M Buy
60,387
+57,870
+2,299% +$7.8M 0.03% 439
2020
Q1 		$273K Buy
+2,517
New +$291K ﹤0.01% 866
2018
Q4 		– Sell
-1,427
Closed -$125K – 967
2018
Q3 		$125K Hold
1,427
– – ﹤0.01% 935
2018
Q2 		$141K Hold
1,427
– – ﹤0.01% 920
2018
Q1 		$170K Buy
+1,427
New +$184K ﹤0.01% 895
2015
Q3 		– Sell
-2,980
Closed -$357K – 766
2015
Q2 		$357K Buy
+2,980
New +$356K ﹤0.01% 702

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Robeco Institutional Asset Management's ALNY Position: Q2 2026 in Review

Robeco Institutional Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 49% in Q2 2026, buying an estimated $18.6M and bringing the position to 188,084 shares worth $56.6M. The position accounts for 0.07% of the portfolio, ranked #247.

Robeco Institutional Asset Management first reported a position in ALNY in Q2 2015 and has held it in 29 quarters since. The position peaked at $57.5M in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Robeco Institutional Asset Management held 188,084 shares of Alnylam Pharmaceuticals worth $56.6M as of Q2 2026.
  • Robeco Institutional Asset Management bought 61,621 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $18.6M.
  • Alnylam Pharmaceuticals made up 0.07% of Robeco Institutional Asset Management's portfolio in Q2 2026, its #247 holding.
  • Robeco Institutional Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 29 quarters since.
  • Robeco Institutional Asset Management's Alnylam Pharmaceuticals position peaked at $57.5M in Q4 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.